Patient Home Monitoring (PHM) Announces Correction to Notice of Annual and Special Meeting of Shareholders and Information Ci...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.


Patient Home Monitoring Corp. (TSX VENTURE:PHM) ("PHM") announced that it is
mailing to shareholders a corrected Notice of Annual and Special Meeting of
Shareholders and Information Circular with an amendment. Shareholders should
expect to receive the corrected version with the amendment within a week.


Mr. Kusher is no longer on the slate of Directors to reflect the announcement on
March 25th, 2014 (PHM Announces Execution of Letter of Intent (LOI) with
Acquisition Target with $14 Million in Annual Revenue; a Re-Alignment of Senior
Management to Better Reflect Growth Strategy). Additionally, with respect to the
proposed Acquisition of HeartHealth4Me, corrections relate to the number of
shares issued in connection with the growth. According to the Board resolution
and Purchase Agreement, the number of shares to be issued should be 16,300
rather than 163,000. The correct language relating to the shares due and Earn
Out Payment in paragraph 3 on page 8 is:


"HH4Me has cash of $104,000, and no material debt. HH4M has three shareholders,
Mssrs. Dalsin and Greene hold "Class B" shares of HH4M and an additional
unrelated and unaffiliated third party to the Company holds "Class A" shares.
The Company can acquire HeartHealth4Me for an initial payment of 750,000 shares
of PHM stock, which stock shall be conveyed to the unaffiliated third party.
Shareholder approval is sought, however, because a corporation affiliated with
two directors of the Company, Messrs. Dalsin and Greene, would have the right to
receive shares in the Company over a three-year period in the event that Annual
Adjusted EBITDA of the Company grows. For each $10,000 in Annual Adjusted EBITDA
Growth, the Company would issue 16,300 common shares of the Company ("Earn Out
Payment"). To avoid excessive shareholder dilution, the number of shares to be
issued in the Earn Out Payment over the three-year period is capped at
15,800,000 shares. In the event that the Company is sold or subject to a change
in control, however, the Earn Out Payment becomes automatically due and
payable."


The correct language for the first sentence of the third full paragraph on page
9 is:


"The Class B shareholders of HH4M shall be issued 1.63 common shares of the
Company for each dollar of Growth in Annual Adjusted EBITDA."


If any shareholder does not receive the amendment by the end of next week, the
amendment will be available at the company website. Any shareholder that voted a
proxy and wishes to change the vote may revoke the proxy as provided in the
Notice, or may contact their broker for assistance. To assist in this process,
the Company will also mail new proxies to shareholders along with the amendment.


About PHM

The explosive growth in the number of elderly patients in the US healthcare
market is creating pressure to provide more efficient delivery systems.
Healthcare providers, such as hospitals, physicians and pharmacies, are seeking
partners that can offer a range of products and services that improve outcomes,
reduce hospital readmissions, and help control costs. PHM fills this need by
delivering a growing number of specialized products and services to achieve
these goals. PHM is a positive cash flow and profitable company that serves
patients with heart disease and other chronic health conditions, this operation
is a platform for acquisitions and organic growth. PHM is focused on a highly
fragmented and developing market of small privately-held companies servicing
chronically ill patients with multiple disease states caused mainly by age and
obesity. Because of the new and highly fragmented nature of the market, PHM is
actively working to identify and evaluate profitable, annuity-based companies to
acquire their patient databases and technical expertise at favorable prices.
PHM's post acquisition organic growth strategy is to increase annual revenue per
patient by offering multiple services to the same patient, consolidating the
patient's services and making life easier for the patient. The expected result
is growing EPS with each acquisition and growing revenue and profits from the
cross selling efforts.


These Adjusted EBITDA figures are unaudited and may change subject to due
diligence and closing procedures. They are intended only as an estimate of
trailing twelve month Adjusted EBITDA of the combined entities and are not meant
to convey forward looking information. Adjusted EBITDA is a Non-IFRS measure the
Company uses as an indicator of financial health, and excludes several items
which may be useful in the consideration of the financial condition of the
Company, including interest expense, taxes, depreciation, amortization, stock
based compensation, and owner compensation.


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, low profit market segments
as well as general economic, market and business conditions, and could differ
materially from what is currently expected.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


This press release does not constitute and the subject matter hereof is not, an
offer for sale or a solicitation of an offer to buy, in the United States or to
any "U.S. Person" (as such term is defined in Regulation S under the U.S.
Securities Act of 1933, as amended (the "1933 Act")) of any equity or other
securities of PHM. The securities of PHM have not been registered under the 1933
Act and may not be offered or sold in the United States (or to a U.S. Person)
absent registration under the 1933 Act or an applicable exemption from the
registration requirements of the 1933 Act.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Patient Home Monitoring Corp.
Michael Dalsin
Chairman
(323) 253-3055
Patient Home Monitoring Corp. (TSXV:PHM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024